Upregulation of SET Expression by BACE1 and its Implications in Down Syndrome

作者：Zhang Xiaozhu; Wu Yili; Duan Xiaoling; Chen Wei; Zou Haiyan; Zhang Mingming; Zhang Shuting; Cai Fang; Song Weihong^*

来源：Molecular Neurobiology, 2015, 51(2): 781-790.

DOI：10.1007/s12035-014-8782-x

• BACE1
• SET
• Down syndrome
• Alzheimer's disease

Down syndrome (DS) is one of the most common genetic diseases. Patients with DS display growth delay and intellectual disabilities and develop Alzheimer's disease (AD) neuropathology after middle age, including neuritic plaques and neurofibrillary tangles. Beta-site amyloid beta precursor protein (APP) cleaving enzyme 1 (BACE1), essential for A beta production and neuritic plaque formation, is elevated in DS patients. However, its homolog, beta-site APP cleaving enzyme 2 (BACE2), functions as theta-secretase and plays a differential role in plaque formation. In this study, by using Two-dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis (2D SDS-PAGE) and LC-MS/MS proteomic profiling analysis, we found that the SET oncogene protein (SET) expression was associated with BACE1 but not BACE2. SET protein was increased in BACE1 overexpressing cells and was markedly reduced in the BACE1 knockout mice. We found that the overexpression of BACE1 or SET significantly inhibited cell proliferation. Moreover, knockdown of SET in BACE1 overexpression cells significantly rescued BACE1-induced cell growth suppression. Furthermore, both BACE1 and SET protein levels were increased in Down syndrome patients. It suggests that BACE1 overexpression-induced SET upregulation may contribute to growth delay and cognitive impairment in DS patients. Our work provides a new insight that BACE1 overexpression not only promotes neuritic plaque formation but may also potentiate neurodegeneration mediated by SET elevation in Alzheimer-associated dementia in DS.

• 出版日期2015-4
• 单位重庆医科大学